AstraZeneca PLC $AZN Stake Boosted by Dillon & Associates Inc.

Dillon & Associates Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,195 shares of the company’s stock after acquiring an additional 1,013 shares during the quarter. Dillon & Associates Inc.’s holdings in AstraZeneca were worth $1,764,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. NewSquare Capital LLC grew its stake in AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after acquiring an additional 218 shares in the last quarter. Larson Financial Group LLC grew its stake in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after acquiring an additional 289 shares in the last quarter. Richardson Financial Services Inc. grew its stake in AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares in the last quarter. Costello Asset Management INC purchased a new position in AstraZeneca during the 1st quarter valued at about $29,000. Finally, Maseco LLP purchased a new position in AstraZeneca during the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent research reports. Berenberg Bank set a $97.00 price target on AstraZeneca in a research note on Wednesday, July 9th. Jefferies Financial Group started coverage on AstraZeneca in a report on Monday, October 27th. They issued a “buy” rating for the company. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Down 0.8%

Shares of AZN stock opened at $81.72 on Tuesday. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $86.57. The firm has a market cap of $253.45 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 1.52 and a beta of 0.36. The stock has a 50 day moving average of $81.17 and a 200-day moving average of $75.18. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.